Novartis closes on EU approval for SMA gene therapy Zolgensm...

Novartis publishes long-term data from SMA gene therapy

Novartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting disease spinal muscular atrophy – information that will be closely

Novartis results show Zolgensma early growth wasn’t a fluke

Novartis pulls rival to Roche’s risdiplam in SMA, says marke...

FDA cues up May verdict for Roche’s SMA challenger risdiplam

FDA slaps hold on Zolgensma trials as animal data raises saf...